Fox Haley M, Rotolo Shannon M
J Pediatr Pharmacol Ther. 2021;26(3):306-310. doi: 10.5863/1551-6776-26.3.306. Epub 2021 Mar 31.
Biologic agents, including anti-immunoglobulin E (omalizumab) and anti-interleukin 5 (mepolizumab), target different mediators involved in the inflammatory process and may work synergistically to decrease symptoms in patients with severe asthma. Here we describe a 12-year-old female on 2 biologic agents, omalizumab and mepolizumab, to control severe persistent asthma. Omalizumab was started years earlier with an initial response; however, her asthma again became uncontrolled and mepolizumab was added. Both biologics were administered concomitantly for over 6 months with marked improvement of asthma symptoms without significant side effects. A combination of biologic agents may be a potential therapy for pediatric patients with severe persistent asthma that remains uncontrolled on a single agent.
生物制剂，包括抗免疫球蛋白E（奥马珠单抗）和抗白细胞介素5（美泊利单抗），作用于炎症过程中不同的介质，可能协同发挥作用以减轻重度哮喘患者的症状。在此，我们描述一名12岁女性，使用两种生物制剂奥马珠单抗和美泊利单抗来控制重度持续性哮喘。奥马珠单抗在数年前开始使用，最初有反应；然而，她的哮喘再次失去控制，于是加用了美泊利单抗。两种生物制剂联合使用超过6个月，哮喘症状显著改善，且无明显副作用。对于单药治疗仍无法控制的重度持续性哮喘患儿，联合使用生物制剂可能是一种潜在的治疗方法。
